This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Glenmark Pharmaceuticals Limited
Drug Names(s): SAR292833, SAR 292833, GRC 17173
Description: GRC 15300 is a novel, potent and selective human transient receptor potential vanilloid (TRPV-3)receptor antagonist.
The Transient Receptor Potential Vanilloid 3 (TRPV3) is a family of nonselective cation channels (meaning that various positively charged ions can pass through equally well) that function in a variety of processes, including temperature sensation and regulation of blood vessel constriction. TRPV3 is expressed in a variety of tissue, and the temperature sensitive members of this family are expressed in subsets of sensory neurons that terminate in the skin, and are activated at distinct physiological temperatures. This channel is activated at temperatures between 22 and 40 degrees C. It is strongly sensitized by various repeated stimuli such as heat, camphor, 2-aminoethyl diphenylborate (2-APB), carvacrol, thymol and eugenol indicating a potential role in nociception (sensation of noxious stimuli).
TRPV3 subunits are also co-expressed with TRPV1 where they form heteromultimeric structures (group of different proteins) by interacting with TRPV1 monomers.
TRPV3 receptor antagonists are also implicated in the treatment of myasthenic syndrome, non-insulin dependent diabetes, breast cancer, and there is limited data available suggesting its putative roles in the neurophysiology of pruritis.
Deal Structure: In May 2010, Sanofi-aventis announced that it entered into a license agreement with Glenmark Pharmaceuticals for the development and commercialization of novel agents to treat chronic pain. Those agents are vanilloid receptor (TRPV3) antagonist molecules, including GRC 15300,
Under the terms of the agreement, Glenmark will receive an upfront payment as well as development, regulatory and commercial milestone payments. All such payments could reach a total of U.S. $325 million. In addition, Glenmark is eligible to receive tiered royalties on sales of products commercialized under the license. Sanofi-aventis will have exclusive marketing rights in North America, European Union and Japan, subject to Glenmark's right to co-promote the products in the United States and five Eastern European countries. Sanofi-aventis will also have co-marketing rights in 10 other countries including Brazil, Russia and China whereas Glenmark will retain exclusive rights in India and other countries of...See full deal structure in Biomedtracker
GRC 15300 News
Additional information available to subscribers only: